Zenosense, a
healthcare technology company, is focusing on developing a novel device to
detect the Methicillin-resistant Staphylococcus aureus (MRSA) “Super-Bug”
frequently found in the human respiratory tract and on the skin. The company
with its advance sensory technology is developing more efficient MRSA detectors
that act like smoke alarms. This will enable it to grab the demands from
hospitals for detecting health-associated infections (HAIs).
The MRSA-detecting
device gives Zenosense a greater growth opportunity, as, according to CDC
estimates, one out of every 20 hospitalized patients in the U.S. can be
infected with HAI, and the annual cost of treating hospitalized MRSA patients
is around $4.2 billion. MRSA-infected patients require three times longer
hospital stays at three times the cost compared to uninfected patients. These
patients are five times more likely to die than other patients. This bacterial
contamination affects around two million patients each year and is responsible
for annual deaths of more than 100,000 and around 23,000 deaths per year in the
U.S. alone. Zenosense is working on its technology to develop and market a
device that will enhance the MRSA detection capability, and help it to treat
these infected patients. The MRSA device will position the company it to take
advantage of this opportunity in the sensory device market.
Extending contract
to enhance device portfolio
The company to
deepen its footprint has extended its agreement with the Sgenia Group to expand
its device portfolio by developing cancer sensory devices. Under this extension
contract, Zenosense has the optional right to fund the development of
prospective cancer sensory devices that may be based on the Sgenia technology.
Based on the funding, Zenosense will have the right to develop, market, and
sell the devices based on Sgenia technology. This will allow Zenosense to
enhance its expertise in developing new cancer sensory devices. The sensory
technology and algorithmic processing in developing the MRSA detection could be
used for developing cancer sensory devices.
Cancers such as lung
and colon produce volatile organic compounds (VOCs) in an individual’s breath
in a similar way to patients infected with MRSA. VOCs are the large group of
carbon-based chemicals that can be easily inhaled by humans and can cause
severe toxicity. Zenosense’s capabilities and small modification in MRSA
detection technology enable the company to develop a device that can detect
lung and colon cancer. The low cost, rapid detection device for these cancers
is expected to have significant long-term demands.
These types of
devices can detect, for example, lung cancer at its initial stage, and on a
mass scale. Lung cancer is typically diagnosed at a late stage when only 25% of
the cases can be treated; however, early detection could have a cure rate of
more than 70%. Prevention practices can reduce the occurrence of HAIs by around
70%, possibly saving $25 billion to $31.5 billion in medical costs in the U.S.
Strong demand for
the cost-effective MRSA detector is expected, driven by higher costs related to
late-stage detection of MRSA. Zenosense through its subsidiary, ZenonBioSytem,
estimated that it can manufacture these devices with the cost of less than $100
per device, and the cost can be reduced to as low as $50 per device. Zenosense
will use established Sgenia programming and patent-pending hardware to develop
a single sensor that will perform an infinite number of scans, creating tens of
thousands of “virtual sensors,” for which other devices require 32 sensors.
This will generate a huge cost savings over an array of individual sensors. The
low-cost, compact design of the Zenosense device can be worn by individuals in
highly sensitive areas in the hospitals.
Zenosense’s MRSA
detector will enable it to enhance its presence in the MRSA detection device
market.
The e-nose devices
available cost around $8,000 each. Zenosense by developing a device 160 times
less expensive with superior super-bug detecting capabilities could seize this
opportunity, which would in turn generate revenue long term.
Conclusion
By extending the
agreement with Sgenia group, Zenosense will have the right to use Sgenia’s
technology to improve its efficacy in developing the cost-effective MRSA
detectors. This would reduce Zenosense’s operating cost, which was around
$448,000 as of December 31. The development and exclusive license agreement
also includes cancer sensory devices, and the capabilities of its MRSA device
to detect lung and colon cancer will strengthen the company’s financial
position.
For more information
on the company visit www.zenosense.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment